UBT251
Other research peptides · no supplier in this ledger publishes a price · 14 registered studies · 1 indexed paper
This page holds one record. The research figures below come from the public registries named under each one, each read on the date printed beside it. No supplier in this ledger prices this compound, so this page carries that half and nothing else. Nothing here was produced by this publication measuring anything.
Identity and computed properties
No PubChem compound record is pinned for this name, so no computed formula and no computed mass is printed here.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
An intervention search of clinicaltrials.gov for the term UBT251, read on 2026-09-20, returned 14 registered studies: 3 phase 1, 6 phase 2 and 5 phase 3.
The United Bio-Technology (Hengqin) Co., Ltd. is lead sponsor on 10 of the 14 records. The remaining 4 name 1 other organization.
On the date read, the statuses those records carried were 9 recruiting, 3 not yet recruiting and 2 completed.
The earliest record the search returns is NCT07134335, first submitted 2025-08-13. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 1 record for the term UBT251 on 2026-09-20. None of the 1 carries a clinical-trial publication type. 0 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
A Drugs@FDA query on 2026-09-20 returned no application record for any of these 6 searches:
- openfda.generic_name:"UBT251"
- openfda.substance_name:"UBT251"
- openfda.brand_name:"UBT251"
- openfda.generic_name:"UBT-251"
- openfda.substance_name:"UBT-251"
- openfda.brand_name:"UBT-251"
Those are results for the 6 searches printed above, and nothing wider. A compound holding an approved application under a name none of those searches covers would not answer any of them, and no dated note of which names were checked, and why those are the ones to check, is recorded here.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
No doctor prescribes this. There is no approved product under this name on the Food and Drug Administration record, read 2026-09-20, so there is no label naming who must avoid it and why.
Read this as missing information, not as a clear record. Nobody has published who is at risk, which is not the same as nobody being at risk.
What has not been published
- None of the 1 indexed records carries a clinical-trial publication type, so the human lane of this record is empty.
- No PubChem compound record is pinned for this name, so no computed formula and no computed mass appears above.
Where a line above says nothing has been compiled here, that is a gap in this publication's record. Where it says nothing is indexed or registered, that is a gap in the public record.
Prices
No supplier tracked by this publication publishes a price for this compound. That was checked against every supplier record in the ledger rather than assumed. A compound can be studied without being sold, and this is one.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-20. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-20. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-20.